Abstract
Purpose: To estimate the rate of new-onset seizure in ADHD patients in relation to ADHD pharmacotherapy. Methods: A retrospective cohort study of 34,727 patients, ages 6 to 17, with at least two insurance claims bearing ADHD diagnoses during 2003 in the United Healthcare database. Incidence of seizure was calculated for observation time during treatment with atomoxetine and stimulants/bupropion. Results: Seizure incidence among ADHD patients was 4.5/1,000 person-years (p-y; 95% confidence interval 3.7 – 5.5). ADHD patients who received any ADHD medication had an incidence of 3.8/1,000 p-y (3.0 – 4.8) compared to 8.7 (5.8 – 12.4) for patients who did not receive any ADHD medication. The relative risk (RR) for current vs non-use of atomoxetine was 1.1 (0.6 – 2.1). For stimulants and bupropion, the RR for current vs non-use was 0.8 (0.6 – 1.3). Elevated seizure risks were found in association with central nervous system (CNS) disease (OR 3.9, 1.2 – 10.9), CNS medications (OR 2.2, 1.3 – 3.6), metabolic disease (OR 2.9, 1.1 – 6.8), and psychiatric disease risk factors (OR 1.7, 1.1 – 2.6). Conclusions: In this study, there was no statistically significant association between use of atomoxetine or stimulants and seizure risk in children ages 6 to 17 years with ADHD and without prior seizure disorder.
Keywords: ADHD, epilepsy, seizure, stimulants, atomoxetine, retrospective cohort study
Current Drug Safety
Title: The Effect of Pharmacotherapy for Attention Deficit Hyperactivity Disorder on Risk of Seizures in Pediatric Patients as Assessed in an Insurance Claims Database
Volume: 3 Issue: 2
Author(s): Andrew T. McAfee, Karen C. Holdridge, Catherine B. Johannes, Kenneth Hornbuckle and Alexander M. Walker
Affiliation:
Keywords: ADHD, epilepsy, seizure, stimulants, atomoxetine, retrospective cohort study
Abstract: Purpose: To estimate the rate of new-onset seizure in ADHD patients in relation to ADHD pharmacotherapy. Methods: A retrospective cohort study of 34,727 patients, ages 6 to 17, with at least two insurance claims bearing ADHD diagnoses during 2003 in the United Healthcare database. Incidence of seizure was calculated for observation time during treatment with atomoxetine and stimulants/bupropion. Results: Seizure incidence among ADHD patients was 4.5/1,000 person-years (p-y; 95% confidence interval 3.7 – 5.5). ADHD patients who received any ADHD medication had an incidence of 3.8/1,000 p-y (3.0 – 4.8) compared to 8.7 (5.8 – 12.4) for patients who did not receive any ADHD medication. The relative risk (RR) for current vs non-use of atomoxetine was 1.1 (0.6 – 2.1). For stimulants and bupropion, the RR for current vs non-use was 0.8 (0.6 – 1.3). Elevated seizure risks were found in association with central nervous system (CNS) disease (OR 3.9, 1.2 – 10.9), CNS medications (OR 2.2, 1.3 – 3.6), metabolic disease (OR 2.9, 1.1 – 6.8), and psychiatric disease risk factors (OR 1.7, 1.1 – 2.6). Conclusions: In this study, there was no statistically significant association between use of atomoxetine or stimulants and seizure risk in children ages 6 to 17 years with ADHD and without prior seizure disorder.
Export Options
About this article
Cite this article as:
McAfee T. Andrew, Holdridge C. Karen, Johannes B. Catherine, Hornbuckle Kenneth and Walker M. Alexander, The Effect of Pharmacotherapy for Attention Deficit Hyperactivity Disorder on Risk of Seizures in Pediatric Patients as Assessed in an Insurance Claims Database, Current Drug Safety 2008; 3 (2) . https://dx.doi.org/10.2174/157488608784529233
DOI https://dx.doi.org/10.2174/157488608784529233 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Peptides as Signaling Inhibitors for Mammalian MAP Kinase Cascades
Current Pharmaceutical Design mRNA as a Versatile Tool for Exogenous Protein Expression
Current Gene Therapy Parkinson’s Disease: Is there a Role for Dietary and Herbal Supplements?
CNS & Neurological Disorders - Drug Targets The Role of Venous Abnormalities in Neurological Disease
Reviews on Recent Clinical Trials Proinflammatory Cytokines and Chemokines in Neonatal Brain Damage
Current Pediatric Reviews Vaccines for Patients with COPD
Recent Patents on Inflammation & Allergy Drug Discovery The Use of the Inhibitory Receptors for Modulating the Immune Responses
Current Pharmaceutical Design Withdrawal Notice: Comparison of Pharmaceutical Effect of Alemtuzumab and Natalizumab and Their Side Effects in Treatment of Various Stages of Multiple Sclerosis Patients
CNS & Neurological Disorders - Drug Targets Recent Updates on Development of Drug Molecules for Human African Trypanosomiasis
Current Topics in Medicinal Chemistry Ewing Sarcoma Family Tumors: Past, Present and Future Prospects
Current Cancer Therapy Reviews Withdrawn: Effects of Tofacitinib on Tfr/Tfh Balance and Expression of CXCL13 and TGF-β1 in Experimental Autoimmune Encephalomyelitis Rats
CNS & Neurological Disorders - Drug Targets Plant and Animal Steroids a New Hope to Search for Antiviral Agents
Current Medicinal Chemistry A Review of Recent Patents on the ASICs as a Key Drug Target
Recent Patents on Biotechnology Pentapeptides as Minimal Functional Units in Cell Biology and Immunology
Current Protein & Peptide Science Heterocycles in the Treatment of Neglected Tropical Diseases
Current Medicinal Chemistry Dengue Virus RNA Polymerase NS5: A Potential Therapeutic Target?
Current Drug Targets Mentha L. Species (Lamiaceae) as Promising Sources of Bioactive Secondary Metabolites
Current Pharmaceutical Design Development of Liposomes and Pseudovirions with Fusion Activity for Efficient Gene Delivery
Current Gene Therapy Natural Chemical Entities as Bioactive Moiety from Weaver Ant, <i>Oecophylla smaragdina</i>: An In Vitro and In-silico Study
Letters in Drug Design & Discovery Small Non-Coding RNAs as Biomarkers
Recent Patents on Biomarkers